Equity L/S Analyst | Forensic Accounting | India, Yellowstone Equity

Ankit Agrawal, CFA

I possess investment research experience across asset classes and geographies, acquired at Investcorp (New York) and Howe & Rusling (Rochester). At Investcorp, an alternative asset manager, I was part of an investment team managing >$1bn in discretionary client assets. I was also a member of investment recommendation, monitoring, cross-asset strategy and macro outlook committees that met periodically for investment decisions and top-down views. At Howe & Rusling, a long-only asset manager, I helped cover US large-cap equity investments across sectors for growth and income focused portfolios as well as assisted in managing a US small-cap growth focused equity portfolio. I possess an MBA in finance and corporate accounting from University of Rochester in US, a CFA Charter, and an Engineering degree from Indian Institute of Technology Bombay in India.  

My current focus is L/S equity fundamental research across market cap and sectors with an eye on corporate governance and forensic accounting. I am currently based in India and my current coverage universe is biased towards India.

-------------
Regulatory Disclosure: Note that Ankit Agrawal (Proprietor of Yellowstone Equity) is a SEBI registered Research Analyst (Registration No.: INH000007216). Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Research Analyst Contact Details -
Address: A-602, Titanium Business Park, Makarba, Ahmedabad - 380051 |
Email: services@yellowstoneequity.com |
Mobile: +91-7575817289

Compliance/Grievance Officer -
Name: Ankit Agrawal |
Email: services@yellowstoneequity.com |
Mobile: +91-7575817289
-------------

Equity L/S Analyst | Forensic Accounting | India

Healthcare Global: An Attractive Spread Trade

HCG Update: New CEO and Subsidiary Acquisition

Smartkarma Corporate Webinar | HealthCare Global: New Opportunities in Cancer Care in India

Healthcare Global Enterprises- Q1 FY18 Results Update

Healthcare Global Enterprises- Q4FY17 and 12 Month FY17 Results Update

Equity Bottom-Up

HealthCare Global Enterprises / Equity Bottom-Up

<p>In this insight, I want to present my investment thesis on <a href="https://www.smartkarma.com/entities/healthcare-global-enterprises-limited" target="_blank" data-smartkarma-citation="entities:23983:1" rel="noopener">Healthcare Global Enterprises (HCG IN)</a>, a fast growing cancer care specialist in India. While I think highly of this cancer care focused hospital chain and consider it as an attractive equity bottom-up opportunity, recent announcements make us believe that it is an attractive event-driven opportunity as well. With today's (June 4) deal update from CVC, a PE player, to buy a ~29% stake in HCG at INR 130 per share, upping their bid from their prior offer of INR 100 per share on May 7, HCG has become an interesting event play. It closed today at INR 119.75 per share, suggesting that the stock is trading at a gross spread of 8.5%+ relative to the offer price.</p>

In this insight, I want to present my investment thesis on Healthcare Global Enterprises (HCG IN), a fast growing cancer care specialist in India. While I think highly of this cancer care focused hospital chain and consider it as an attractive equity bottom-up opportunity, recent announcements make us believe that it is an attractive event-driven opportunity as well. With today's (June 4) deal update from CVC, a PE player, to buy a ~29% stake in HCG at INR 130 per share, upping their bid from their prior offer of INR 100 per share on May 7, HCG has become an interesting event play. It closed today at INR 119.75 per share, suggesting that the stock is trading at a gross spread of 8.5%+ relative to the offer price.

Healthcare Global: Best of Both the Worlds | Attractive Event-Driven & Equity Bottom-Up Opportunity